BioCentury
ARTICLE | Clinical News

Chi-Med down on fruquintinib OS miss in third-line NSCLC

November 16, 2018 9:52 PM UTC

Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said third-line treatment with fruquintinib missed the primary endpoint of improving overall survival vs. placebo in the Chinese Phase III FALUCA trial to treat non-small cell lung cancer. Chi-Med lost 1,085p (19%) to 4,515p in London on Friday and was off $6.44 (18%) to $30.16 on NASDAQ.

Chi-Med did not respond to inquiries regarding next steps in time for publication, but Executive Director and CEO Christian Hogg told BioCentury in September that the company planned to submit an NDA for fruquintinib in China with a positive Phase III NSCLC readout...